Zacks Analyst Blog Highlights: Baker Hughes Inc., NovaMed, Inc., Hewitt Associates Inc., BioMarin Pharmaceutical Inc. and VistaPrint Ltd.

CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Baker Hughes Inc. (NYSE: BHI), NovaMed, Inc. (Nasdaq: NOVA), Hewitt Associates Inc. (NYSE: HEW), BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and VistaPrint Ltd. (Nasdaq: VPRT).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Wednesday’s Analyst Blog:

Baker Hughes on Solid Ground

Baker Hughes Incorporated (NYSE: BHI) reported in-line third quarter results with a 12% year-over-year increase in revenue despite disruptions from this year's Gulf Coast hurricanes.

While near-term commodity-price weakness may weigh on the stock price, the company's long-term prospects remain positive, given its leading portfolio of technologies, a significantly expanding international infrastructure, and a solid balance sheet. Baker Hughes Inc. is in excellent financial health, with an investment-grade credit profile and plenty of cash on hand.

NovaMed a Buy Ahead of Report

NovaMed, Inc. (Nasdaq: NOVA) is an emerging healthcare services company engaged in the operation of ambulatory surgery centers (ASCs) and the provision of optical products and services to eye-care professionals. We expect NOVA to report 3Q08 financial results on October 30, 2008.

Our current revenue and EPS estimates are $35M and $0.09, respectively, versus consensus estimates of $36M and $0.09. The company's earnings conference call will also be held tomorrow at 11.00am EST.

Hewitt Associates Sell Maintained

Hewitt Associates Inc. (NYSE: HEW) is the clear leader in the emerging human resources BPO (business process outsourcing) market. But with the unemployment rate having risen to 6.1% in August, the expected economic weakness should hamper the financial results of employment-related companies such as Hewitt Associates.

The Sell rating is maintained due to expected economic weakness in the next few quarters. Employment service companies generally participate in the later stage of economic recovery.

BioMarin a Buy Up to $28

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) develops enzyme therapies for serious chronic genetic disorders and other diseases. Its leading product, Aldurazyme, is used for treating the ultra-rare genetic disorder mucopolysaccharidosis-I (MPS-I) while its second product, Naglazyme, is appoved for the treatment of MPS-VI. Recently, the company received FDA approval for its third product, Kuvan, for the treatment of PKU.

Strong product sales will drive the company to profitability in 2008 and beyond. The company's clinical pipeline remains impressive, as well. As such, we maintain our Buy rating on the stock with a price target of $28.

VistaPrint Turning Out Cash

VistaPrint Ltd. (Nasdaq: VPRT) is an online supplier of high-quality graphic design services and customized printed products to small businesses and consumers. VistaPrint is the largest company in the industry, and its use of proprietary web-based design software and advanced computer integrated printing facilities, the company has developed a competitive advantage relative to traditional graphic design and printing methods.

We rate shares of VPRT a Buy with a price target of $30.00 per share following the release of Q109 results. VistaPrint is a leading online supplier of high-quality graphic design services and customized printed products to small businesses and consumers. VistaPrint has generated significant organic growth over the last several years, which we project will continue.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.